Cidara Therapeutics (CDTX) Earning Somewhat Positive News Coverage, Study Shows
Media coverage about Cidara Therapeutics (NASDAQ:CDTX) has been trending somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cidara Therapeutics earned a news sentiment score of 0.03 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 47.2912366411594 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Accern’s rankings:
- Brokers Issue Forecasts for Cidara Therapeutics, Inc.’s Q3 2017 Earnings (CDTX) (americanbankingnews.com)
- Cidara Therapeutics, Inc. (CDTX) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
- Equities Analysts Offer Predictions for Cidara Therapeutics, Inc.’s FY2018 Earnings (CDTX) (americanbankingnews.com)
- Leerink Swann Comments on Cidara Therapeutics, Inc.’s Q3 2017 Earnings (NASDAQ:CDTX) (americanbankingnews.com)
Shares of Cidara Therapeutics (NASDAQ:CDTX) traded up 4.25% during mid-day trading on Friday, hitting $6.75. The stock had a trading volume of 116,782 shares. Cidara Therapeutics has a 52 week low of $5.60 and a 52 week high of $12.95. The stock has a 50 day moving average of $7.12 and a 200-day moving average of $7.39. The stock’s market capitalization is $113.83 million.
Cidara Therapeutics (NASDAQ:CDTX) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.91) by $0.08. On average, equities research analysts predict that Cidara Therapeutics will post ($3.62) earnings per share for the current year.
CDTX has been the topic of a number of research analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $11.00 target price on shares of Cidara Therapeutics in a report on Monday, April 24th. BTIG Research reaffirmed a “buy” rating and issued a $20.00 target price (up previously from $15.00) on shares of Cidara Therapeutics in a report on Saturday, April 29th. Wedbush reaffirmed an “outperform” rating and issued a $13.00 target price on shares of Cidara Therapeutics in a report on Tuesday, May 16th. ValuEngine lowered Cidara Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Finally, Zacks Investment Research raised Cidara Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a report on Monday, June 19th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $13.14.
In related news, insider Taylor Sandison bought 20,000 shares of the stock in a transaction that occurred on Wednesday, June 7th. The stock was acquired at an average cost of $5.90 per share, with a total value of $118,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jeffrey Stein bought 15,000 shares of the stock in a transaction that occurred on Monday, June 5th. The shares were bought at an average cost of $5.95 per share, with a total value of $89,250.00. The disclosure for this purchase can be found here. 18.90% of the stock is owned by company insiders.
About Cidara Therapeutics
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Ratings for Cidara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.